Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT06306573 Enrolling by invitation - Clinical trials for Heart Failure NYHA Class III

CardioMEMS HF System Real-World Evidence Post-Approval Study

Start date: December 15, 2022
Phase:
Study type: Observational

The purpose of this post-approval study (PAS) is to evaluate the long-term safety and effectiveness of the CardioMEMS™ HF System using real-world evidence (RWE) methods.

NCT ID: NCT06287996 Enrolling by invitation - Heart Failure Clinical Trials

Effects of Warm Water Footbath Intervention on Sleep Quality , Fatigue and Heart Rate Variability in Patients With Heart Failure

Start date: February 23, 2024
Phase: N/A
Study type: Interventional

This study adopted an experimental research design to explore the effects of a warm water foot bath program on fatigue, sleep, and heart rate variability in patients with heart failure. The subjects of the study were heart failure patients in the cardiology outpatient department. The patients were randomly assigned to the experimental group and the control group. The control group received routine care and wore an actigraph. The experimental group received 4 additional care in addition to routine care and wearing an actigraph. Weekly warm water foot bath, data collection includes subjective sleep quality and fatigue level, physiological measurements: sleep quality-sleep time and efficiency, and heart rate variability index.

NCT ID: NCT06195982 Enrolling by invitation - Clinical trials for Heart Failure With Reduced Ejection Fraction

Ketones in Heart Failure With Reduced Ejection Fraction

HFrEF
Start date: March 6, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to understand the effects of a ketone drink on exercise capacity and other cardiovascular parameters in patients with heart failure. In heart failure, patients are limited in their ability to do all the things they want to do, and exercise as much as they would like, due to becoming tired and short of breath early. There may be several reasons why these symptoms occur. This study is assessing whether the ketone drink can improve these symptoms. This drink has been given status by Food and Drug Administration as "generally regarded as safe". The use of DeltaG in this study is experimental. DeltaG has not been approved by the Food and Drug Administration (FDA) for the use being evaluated in this study.

NCT ID: NCT06149195 Enrolling by invitation - Clinical trials for Rest Gated Myocardial Perfusion Imaging in Heart Failure

18F-MFBG Cardiac Imaging for Heart Failure Administration

Start date: January 1, 2024
Phase:
Study type: Observational

The clinical feasibility of 18F-FMBG cardiac PET imaging will be observed in sympathetic nervous system activity in patients with heart failure, predicted cardiac events, guided ICD implantation, and evaluated therapy efficiency.

NCT ID: NCT06122961 Enrolling by invitation - Heart Failure Clinical Trials

Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

POSEIDON
Start date: November 15, 2023
Phase:
Study type: Observational

This study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease). Participants will continue their normal care and will not get any treatment other than those the study doctor has prescribed.

NCT ID: NCT06107907 Enrolling by invitation - Clinical trials for to Assess the Corresponding PEEP Values in NIV With CPAP Under Different Airflow Rates During HFOT in Heart Failure Patients

Using Electrical Impedance Tomography to Investigate the Relationship Between Airflow Rate During High-flow Oxygen Therapy and Pressure in Patients With Heart Failure Compared to Non-invasive Ventilation

Start date: November 15, 2023
Phase: N/A
Study type: Interventional

Non-invasive ventilation (NIV) has been widely used in heart failure patients with supporting evidence. However, the drawbacks and contraindications associated with NIV limit its applicability in certain patients. Recently, high-flow oxygen therapy (HFOT) has gained popularity, particularly in the context of the COVID-19 pandemic, due to its documented benefits, improved patient comfort and fewer contraindications. Studies have suggested that HFOT can generate positive end-expiratory pressure (PEEP) similar to NIV, thereby increasing end-expiratory lung volume. However, the specific effects of PEEP remain unknown, as previous research only monitored the upper airway pressure. Therefore, this study aims to explore the flow-pressure relationship between HFOT and NIV in heart failure patients using electrical impedance tomography (EIT). This prospective randomized crossover clinical trial will be conducted at a single medical center with multiple intensive care units. Participants will be randomly assigned to Groups A and B using a computerized randomization process. Each group will undergo specific protocols for 5-10 minutes per phase, during which parameters including respiratory rate, heart rate, blood pressure, peripheral oxygen saturation, and oxygen concentration will be recorded. NIV will be administered in continuous positive airway pressure (CPAP) mode. Additional parameters such as tidal volume, respiratory rate, minute ventilation, leak flow, and peak inspiratory pressure will be recorded for NIV. The study protocols for Group A will follow the sequence of oxygen mask, HFOT 40L, HFOT 50L, HFOT 60L, oxygen mask, CPAP 4cmH2O, CPAP 5cmH2O, and CPAP 6cmH2O. Group B will follow the sequence of oxygen mask, CPAP 4cmH2O, CPAP 5cmH2O, CPAP 6cmH2O, oxygen mask, HFOT 40L, HFOT 50L, and HFOT 60L. This means that each intervention will be performed in the order listed, with one intervention completed before moving on to the next. The participants will be positioned in a semi-recumbent position at 45 degrees, and the EIT belt will be placed around the fifth (or sixth) intercostal space for monitoring. The EIT signals will be filtered with a cut-off frequency set at 10 beats below the current heart rate. The entire procedure is estimated to take approximately 1-1.5 hours, and recalibration will only be performed in case of significant signal abnormalities. All data will be stored for offline analysis.

NCT ID: NCT06036914 Enrolling by invitation - Clinical trials for Heart Failure; With Decompensation

A Study of Ultra High Dose Diuretics to Treat Heart Failure

Start date: November 27, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of ultrahigh dose diuretics compared to standard dose diuretics over 24 hours in patients with decompensated heart failure.

NCT ID: NCT05989945 Enrolling by invitation - Stroke Clinical Trials

HIDRAdenitis Suppurativa and HEART Disease

Start date: August 1, 2023
Phase:
Study type: Observational

In a prospective observational cohort study (n = 250) the investigators aim to assess the correlation between cardiac biomarkers, advanced echocardiography and HS severity and determine whether these are prognostic markers of heart disease in patients suffering from hidradenitis suppurativa (HS).

NCT ID: NCT05952999 Enrolling by invitation - Hypertension Clinical Trials

Analysis of the Virtual Acute Care at Home Experience

HaH
Start date: August 15, 2023
Phase:
Study type: Observational

The purpose of this study is to examine the implementation, intervention effectiveness, and dissemination of a digital acute care delivery model for improving selected health outcomes in the Hospital at Home population.

NCT ID: NCT05948332 Enrolling by invitation - Respiratory Failure Clinical Trials

Definition and Management of Right Ventricular Injury in Adult Patients Receiving Extracorporeal Membrane Oxygenation

Start date: September 1, 2023
Phase:
Study type: Observational

The aim of this study is to identify existing definitions and therapeutic approaches for acute right ventricular injury (RVI) in patients receiving extracorporeal membrane oxygenation (ECMO) for respiratory support. The objective of the study is to generate expert consensus statements on the definition and management of acute RVI in this high-risk patient population, using a Delphi method. The standardised RVI definition during ECMO for respiratory support and a consensus-based management approach to RVI will facilitate systematic aggregation of data across clinical trials to harmonise patient selection and compare therapeutic interventions.